Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder, Overactive | 4 | 2021 | 96 | 1.850 |
Why?
|
| Pelvic Organ Prolapse | 5 | 2023 | 170 | 1.760 |
Why?
|
| Surgical Mesh | 4 | 2020 | 125 | 1.240 |
Why?
|
| Vagina | 3 | 2023 | 181 | 1.200 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2019 | 164 | 1.060 |
Why?
|
| Menopause | 2 | 2023 | 90 | 0.840 |
Why?
|
| Quality of Life | 2 | 2023 | 1816 | 0.830 |
Why?
|
| Skin Transplantation | 2 | 2020 | 193 | 0.690 |
Why?
|
| Cost of Illness | 1 | 2021 | 161 | 0.650 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 16 | 0.580 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 514 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 296 | 0.560 |
Why?
|
| Triamcinolone | 1 | 2017 | 20 | 0.510 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2017 | 41 | 0.510 |
Why?
|
| Bupivacaine | 1 | 2017 | 48 | 0.500 |
Why?
|
| Cystitis, Interstitial | 1 | 2017 | 55 | 0.480 |
Why?
|
| Heparin | 1 | 2017 | 187 | 0.480 |
Why?
|
| Urinary Incontinence | 3 | 2023 | 217 | 0.430 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 358 | 0.420 |
Why?
|
| Female | 17 | 2023 | 49980 | 0.330 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2023 | 198 | 0.310 |
Why?
|
| Treatment Outcome | 4 | 2021 | 9228 | 0.240 |
Why?
|
| Humans | 18 | 2023 | 95992 | 0.230 |
Why?
|
| Middle Aged | 7 | 2021 | 28299 | 0.210 |
Why?
|
| Aged | 6 | 2021 | 20927 | 0.200 |
Why?
|
| Atrophy | 1 | 2023 | 131 | 0.200 |
Why?
|
| Surgery, Plastic | 1 | 2023 | 43 | 0.190 |
Why?
|
| Fallopian Tubes | 1 | 2022 | 49 | 0.190 |
Why?
|
| Allografts | 2 | 2020 | 207 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2021 | 10307 | 0.170 |
Why?
|
| Trimethoprim | 1 | 2021 | 15 | 0.170 |
Why?
|
| Ovary | 1 | 2022 | 267 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 85 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7224 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 129 | 0.160 |
Why?
|
| Perception | 1 | 2021 | 185 | 0.160 |
Why?
|
| Urology | 1 | 2021 | 133 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 101 | 0.160 |
Why?
|
| Patient Preference | 1 | 2021 | 126 | 0.160 |
Why?
|
| Cholinergic Antagonists | 1 | 2019 | 30 | 0.160 |
Why?
|
| Cystocele | 1 | 2019 | 7 | 0.150 |
Why?
|
| Recurrence | 2 | 2020 | 1231 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2021 | 362 | 0.150 |
Why?
|
| Uterus | 1 | 2021 | 228 | 0.150 |
Why?
|
| Decision Making | 2 | 2021 | 695 | 0.150 |
Why?
|
| Tibial Nerve | 1 | 2018 | 13 | 0.150 |
Why?
|
| Surgeons | 1 | 2023 | 298 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2021 | 816 | 0.130 |
Why?
|
| Dissection | 1 | 2017 | 45 | 0.130 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2017 | 11 | 0.130 |
Why?
|
| Mullerian Ducts | 1 | 2017 | 20 | 0.130 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 34 | 0.130 |
Why?
|
| Nocturia | 1 | 2017 | 23 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1355 | 0.130 |
Why?
|
| Uterine Prolapse | 1 | 2017 | 82 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 192 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 635 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2018 | 3115 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 789 | 0.110 |
Why?
|
| Tungsten Compounds | 1 | 2014 | 1 | 0.110 |
Why?
|
| Nitrogen Compounds | 1 | 2014 | 3 | 0.110 |
Why?
|
| Graphite | 1 | 2014 | 13 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2860 | 0.110 |
Why?
|
| Hydrogen | 1 | 2014 | 53 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 89 | 0.100 |
Why?
|
| Infant | 1 | 2019 | 3359 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3922 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2019 | 4690 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 5593 | 0.080 |
Why?
|
| Adult | 3 | 2019 | 28636 | 0.080 |
Why?
|
| Dysuria | 1 | 2023 | 8 | 0.050 |
Why?
|
| United States | 1 | 2016 | 7785 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 107 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 202 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2023 | 97 | 0.050 |
Why?
|
| Hippurates | 1 | 2021 | 3 | 0.040 |
Why?
|
| Methenamine | 1 | 2021 | 3 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2021 | 88 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 174 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 198 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 334 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 241 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 445 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 329 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 603 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1561 | 0.040 |
Why?
|
| Reoperation | 1 | 2020 | 712 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2017 | 67 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 286 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 7034 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Electrochemistry | 1 | 2014 | 60 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2014 | 111 | 0.030 |
Why?
|
| Catalysis | 1 | 2014 | 216 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2014 | 1376 | 0.020 |
Why?
|